1
|
Kiguli-Malwadde E, Forster M, Eliaz A, Celentano J, Chilembe E, Couper ID, Dassah ET, De Villiers MR, Gachuno O, Haruzivishe C, Khanyola J, Martin S, Motlhatlhedi K, Mubuuke R, Mteta KA, Moabi P, Rodrigues A, Sears D, Semitala F, von Zinkernagel D, Reid MJA, Suleman F. Comparing in-person, blended and virtual training interventions; a real-world evaluation of HIV capacity building programs in 16 countries in sub-Saharan Africa. PLOS Glob Public Health 2023; 3:e0001654. [PMID: 37486898 PMCID: PMC10365303 DOI: 10.1371/journal.pgph.0001654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 06/05/2023] [Indexed: 07/26/2023]
Abstract
We sought to evaluate the impact of transitioning a multi-country HIV training program from in-person to online by comparing digital training approaches implemented during the pandemic with in-person approaches employed before COVID-19. We evaluated mean changes in pre-and post-course knowledge scores and self-reported confidence scores for learners who participated in (1) in-person workshops (between October 2019 and March 2020), (2) entirely asynchronous, Virtual Workshops [VW] (between May 2021 and January 2022), and (3) a blended Online Course [OC] (between May 2021 and January 2022) across 16 SSA countries. Learning objectives and evaluation tools were the same for all three groups. Across 16 SSA countries, 3023 participants enrolled in the in-person course, 2193 learners participated in the virtual workshop, and 527 in the online course. The proportions of women who participated in the VW and OC were greater than the proportion who participated in the in-person course (60.1% and 63.6%, p<0.001). Nursing and midwives constituted the largest learner group overall (1145 [37.9%] vs. 949 [43.3%] vs. 107 [20.5%]). Across all domains of HIV knowledge and self-perceived confidence, there was a mean increase between pre- and post-course assessments, regardless of how training was delivered. The greatest percent increase in knowledge scores was among those participating in the in-person course compared to VW or OC formats (13.6% increase vs. 6.0% and 7.6%, p<0.001). Gains in self-reported confidence were greater among learners who participated in the in-person course compared to VW or OC formats, regardless of training level (p<0.001) or professional cadre (p<0.001). In this multi-country capacity HIV training program, in-person, online synchronous, and blended synchronous/asynchronous strategies were effective means of training learners from diverse clinical settings. Online learning approaches facilitated participation from more women and more diverse cadres. However, gains in knowledge and clinical confidence were greater among those participating in in-person learning programs.
Collapse
Affiliation(s)
- E Kiguli-Malwadde
- African Center for Global Health and Social Transformation, Kampala, Uganda
| | - M Forster
- Institute for Global Health Sciences, University of California, San Francisco, California, United States of America
| | - A Eliaz
- Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America
| | - J Celentano
- Institute for Global Health Sciences, University of California, San Francisco, California, United States of America
| | - E Chilembe
- Kamuzu College of Nursing, University of Malawi, Kamuzu, Malawi
| | - I D Couper
- Department of Global Health, Ukwanda Centre for Rural Health, Stellenbosch University, Stellenbosch, South Africa
| | - E T Dassah
- School of Public Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - M R De Villiers
- Department of Global Health, Ukwanda Centre for Rural Health, Stellenbosch University, Stellenbosch, South Africa
| | - O Gachuno
- Faculty of Medicine, Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya
| | - C Haruzivishe
- Faculty of Health Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - J Khanyola
- University of Global Health Equity, Kigali, Rwanda
| | - S Martin
- Institute for Global Health Sciences, University of California, San Francisco, California, United States of America
| | - K Motlhatlhedi
- Faculty of Medicine, Department of Family Medicine and Public Health, University of Botswana, Botswana
| | - R Mubuuke
- School of Medicine, Makerere University, Kampala, Uganda
| | - K A Mteta
- Kilimanjaro Christian Medical University College, Kilimanjaro, Tanzania
| | - P Moabi
- Scott College of Nursing, Morija, Lesotho
| | - A Rodrigues
- Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique
| | - D Sears
- Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, California, United States of America
| | - F Semitala
- Faculty of Medicine, Department of Family Medicine and Public Health, University of Botswana, Botswana
| | - D von Zinkernagel
- Institute for Global Health Sciences, University of California, San Francisco, California, United States of America
| | - M J A Reid
- Institute for Global Health Sciences, University of California, San Francisco, California, United States of America
- Department of Medicine, Division of Infectious Diseases, University of California, San Francisco, California, United States of America
| | - F Suleman
- School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
| |
Collapse
|
2
|
Waterhouse D, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel M, Linardou H, Chul-Cho B, Roberts-Thomson R, Okamoto I, Blais N, Schvartsman G, Holmskov K, Chmielewska I, Forster M, Stollenwerk B, Obiozor C, Wang Y, Novello S. 40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00258-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
3
|
Sacher A, Patel M, Miller W, Desai J, Garralda E, Bowyer S, Kim T, De Miguel M, Falcon A, Krebs M, Lee J, Cheng M, Han SW, Shacham-Shmueli E, Forster M, Jerusalem G, Massarelli E, Paz-Ares Rodriguez L, Prenen H, Walpole I, Arbour K, Choi Y, Dharia N, Lin M, Mandlekar S, Royer Joo S, Shi Z, Schutzman J, LoRusso P. OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Forster M, Krebs M, Majem M, Peguero J, Clay T, Felip E, Iams W, Roxburgh P, Doger B, Bajaj P, Kefas J, Scott J.A, Barba Joaquín A, Mueller C, Triebel F. EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Ibrahim NK, Schreek S, Cinar B, Loxha L, Bourquin JP, Bornhauser B, Forster M, Stanulla M, Gutierrez A, Hinze L. SOD2 Promotes Acute Leukemia Adaptation to Amino Acid Starvation
Through the N-Degron Pathway. KLINISCHE PADIATRIE 2022. [DOI: 10.1055/s-0042-1748744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- NK Ibrahim
- Hannover Medical School, Hannover, Germany
| | - S Schreek
- Hannover Medical School, Hannover, Germany
| | - B Cinar
- Hannover Medical School, Hannover, Germany
| | - L Loxha
- Hannover Medical School, Hannover, Germany
| | - J-P Bourquin
- University Children’s Hospital, Zurich,
Switzerland
| | - B Bornhauser
- University Children’s Hospital, Zurich,
Switzerland
| | - M Forster
- Institute of Clinical Molecular Biology, Kiel, Germany
| | - M Stanulla
- Hannover Medical School, Hannover, Germany
| | | | - L Hinze
- Hannover Medical School, Hannover, Germany
| |
Collapse
|
6
|
Graham R, Kolluri K, Davies A, Weil B, Day A, Popova B, Ngai Y, Fullen D, Teixeira V, Forster M, Lowdell M, Janes S. Mesenchymal Stem/Stromal Cells: ANALYSIS OF PATIENT PERIPHERAL BLOOD SAMPLES TO ASSESS IMMUNOGENICITY OF MSCTRAIL, A NOVEL ANTI-CANCER THERAPY. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00168-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Krebs M, Majem Tarruella M, Forster M, Peguero J, Clay T, Felip E, Iams W, Roxburgh P, Doger de Spéville B, Bajaj P, Mueller C, Triebel F. 11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Samuel E, Rologi E, Fraser H, Sassi M, Pruchniak M, Kotsiou E, Robinson J, Benzekhroufa K, Goodsell L, Carolan C, Saggese M, Grant M, Samways B, Kotecha P, Schmitt A, Lawrence D, Forster M, Turajlic S, Lowdell M, Quezada S. 58P Validation of the Achilles VELOS process 2 manufacturing platform for the treatment of solid cancer: GMP scale runs generate a significant dose boost of highly potent clonal neoantigen reactive T-cells. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Lee A, Girling B, Patel G, Sawhney P, Luong M, Ohana D, Forster M, Lee S. MA13.06 Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Zeiner PS, Filipski K, Forster M, Voss M, Fokas E, Herrlinger U, Harter PN, Steinbach JP, Ronellenfitsch MW. P14.11 Severe treatment-induced myelosuppression is more frequent in female malignant glioma patients and associated with reduced overall survival. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab180.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
An association of treatment-related myelotoxicity with female gender has been previously suggested. However, a systematic analysis of the prognostic relevance of radiochemotherapy-related cytopenia involving the different blood cell lineages is lacking.
MATERIAL AND METHODS
We retrospectively analyzed cytopenia during temozolomide-based concomitant radiochemotherapy (RCT) in 493 glioma patients. Histological grading, molecular pathology, surgical procedures and median overall survival (OS) were recorded. The extent of cytopenia was correlated with gender and outcome.
RESULTS
Treatment-induced severe cytopenia (leuko-, lympho-, neutro- and thrombocytopenia) occurred much more often in female than in male glioma patients (40.8 vs. 13.9%, p-value <0.0001). In female patients with IDH-wildtype high-grade astrocytomas there was a negative correlation of severe leuko-, lympho- and thrombocytopenia during temozolomide RCT with OS (36 vs. 54, 37 vs. 54 and 36 vs. 57 weeks, respectively; all p-values <0.05). In male patients there was also a trend for this unfavorable effect. Additionally, severe cytopenia correlated with reduced temozolomide dose exposure during RCT (all p-values <0.05 in total cohort) and reduced dose exposure was independently associated with worse OS (p-values <0.05 in the total and female cohort).
CONCLUSION
Our data confirm that women are at higher risk for treatment-induced cytopenia during RCT which is associated with a significant decrease in OS. From our data, it appears plausible that reduced temozolomide dose exposure during RCT is at least in part responsible for this finding. Immunosuppression of patients with severe cytopenia may be an independent contributor to adverse outcome.
Collapse
Affiliation(s)
- P S Zeiner
- Dr. Senckenberg Institute of Neurooncology, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - K Filipski
- Institute of Neurology (Edinger-Institute), Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - M Forster
- Department of Neurosurgery, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - M Voss
- Dr. Senckenberg Institute of Neurooncology, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - E Fokas
- Department of Radiotherapy and Oncology, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - U Herrlinger
- Division of Clinical Neurooncology, University Hospital Bonn, Bonn, Germany
| | - P N Harter
- Institute of Neurology (Edinger-Institute), Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - J P Steinbach
- Dr. Senckenberg Institute of Neurooncology, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| | - M W Ronellenfitsch
- Dr. Senckenberg Institute of Neurooncology, Goethe University, University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
11
|
Watson M, Chambers P, Shiu KK, Bridgewater J, Desai M, Roylance R, Tailor A, Masento S, Forster M, Al Moubayed N. 1859P Using deep learning with demographic and laboratory values from baseline to cycle 2 to predict subsequent renal and hepatic function. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Forster M, Mendes R, Guerrero Urbano T, Evans M, Lei M, Spanswick V, Miles E, Simões R, Wheeler G, Forsyth S, White L. 866P ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Syeed Z, Forster M, Boukovinas I, Nutting C, Carnell D, Guerrero Urbano T, Sibtain A, Kalavrezos N, Patel G, Al Bakir M, Arkenau HT, Levva S, Gonnet P, Morelli C, Guerriero S, Rofei M, Formica V, Patrikidou A. 889P Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Patel G, Sawhney P, Ohana D, Luong M, Wong Y, Lee A, Forster M. 31P Safety and efficacy of immune checkpoint inhibitors in cancer patients with pre-existing autoimmune disease: A UK tertiary cancer centre experience. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.01.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
15
|
Forster M, Felip E, Doger B, Lopez Pousa A, Carcereny E, Bajaj P, Church M, Peguero J, Roxburgh P, Triebel F. 927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1042] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
16
|
Forsyth S, Yip K, Foran B, Gougis P, Wheeler G, White L, Chandrakumar A, Blair K, Pathak Y, Spanswick V, Lowe H, Hartley J, Forster M. 979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
17
|
Davies A, Sage E, Kolluri K, Graham R, Weil B, Rego R, Bain O, Patrick P, Champion K, Day A, Popova B, Wheeler G, Fullen D, Kalbur T, Forster M, Lowdell M, Janes S. P2.01-16 TACTICAL: A Phase I/II Trial to Assess the Safety and Efficacy of MSCTRAIL in Metastatic Lung Adenocarcinoma. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
18
|
Gomes F, Yip K, Tokaca N, Greystoke A, Escriu C, Conibear J, Ghosh S, Doherty G, Funingana I, Ahmad T, Ahmed S, Cox R, Newsom-Davis T, Mills H, Shah R, Dorey N, Harle A, Dancey G, Baijal S, Geldart T, Ghafoor Q, Tarver K, Talbot T, Forster M, Cove-Smith L, Califano R, Blackhall F, Popat S, Summers Y. The ALK project: a real-world national network and database. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30121-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Herbst R, Garon E, Kim DW, Chul Cho B, Pérez Gracia J, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su WC, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy511.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Herbst R, Garon E, Kim DW, Chul Cho B, Pérez Gracia J, Han JY, Dubos Arvis C, Majem M, Forster M, Monnet I, Novello S, Szalai Z, Gubens M, Su WC, Ceresoli G, Samkari A, Jensen E, Lubiniecki G, Baas P. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.075] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Forster M, Moreno V, Calvo E, Olmedo M, Lopez-Criado M, Lopez-Vilariño J, Nuñez R, Kahatt C, Soto-Matos A. P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.855] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Fennell D, Danson S, Forster M, Talbot D, Woll P, Child J, Ngai Y, Farrelly L, Hackshaw A, Sharkey A, Busacca S, Hastings R, Barnes D, Nicolson M, Taylor P, Ahmed S, Wheeler G. MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
23
|
Forster M, Baumgarten P, Gessler F, Maurer G, Senft C, Hattingen E, Seifert V, Harter P, Franz K. P01.063 Influence of Pregnancy on Glioma Patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Forster
- Goethe University, Frankfurt, Germany
| | | | - F Gessler
- Goethe University, Frankfurt, Germany
| | - G Maurer
- Goethe University, Frankfurt, Germany
| | - C Senft
- Goethe University, Frankfurt, Germany
| | | | - V Seifert
- Goethe University, Frankfurt, Germany
| | - P Harter
- Goethe University, Frankfurt, Germany
| | - K Franz
- Goethe University, Frankfurt, Germany
| |
Collapse
|
24
|
Kilinc F, Noack A, Lortz I, Seifert V, Behrens M, Forster M. P01.164 Cognitive and neuropsychological outcome after awake surgery for left frontal and left temporal tumor resection. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- F Kilinc
- Goethe University, Frankfurt, Germany
| | - A Noack
- Goethe University, Frankfurt, Germany
| | - I Lortz
- Goethe University, Frankfurt, Germany
| | - V Seifert
- Goethe University, Frankfurt, Germany
| | - M Behrens
- Goethe University, Frankfurt, Germany
| | - M Forster
- Goethe University, Frankfurt, Germany
| |
Collapse
|
25
|
Thakur N, Senft C, Seifert V, Forster M. P01.107 Resection of supratentorial lesions employing a combined surgical aspiration and monopolar stimulationdevice. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- N Thakur
- Department of Neurosurgery, Frankfurt am Main, Germany
| | - C Senft
- Department of Neurosurgery, Frankfurt am Main, Germany
| | - V Seifert
- Department of Neurosurgery, Frankfurt am Main, Germany
| | - M Forster
- Department of Neurosurgery, Frankfurt am Main, Germany
| |
Collapse
|
26
|
Steidl E, Zeiner P, Wagner M, Fokas E, Forster M, Ronellenfitsch M, Steinbach JP, Harter PN, Bähr O. P01.101 Treatment and survival of patients with lower grade glioma according to the 2007 and the 2016 WHO classification: A retrospective analysis of 423 patients. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- E Steidl
- University Hospital Frankfurt, Frankfurt, Germany
| | - P Zeiner
- University Hospital Frankfurt, Frankfurt, Germany
| | - M Wagner
- University Hospital Frankfurt, Frankfurt, Germany
| | - E Fokas
- University Hospital Frankfurt, Frankfurt, Germany
| | - M Forster
- University Hospital Frankfurt, Frankfurt, Germany
| | | | | | - P N Harter
- University Hospital Frankfurt, Frankfurt, Germany
| | - O Bähr
- University Hospital Frankfurt, Frankfurt, Germany
| |
Collapse
|
27
|
Kieffer R, Bartnik L, Bergamaschi M, Bleko VV, Billing M, Bobb L, Conway J, Forster M, Karataev P, Konkov AS, Jones RO, Lefevre T, Markova JS, Mazzoni S, Padilla Fuentes Y, Potylitsyn AP, Shanks J, Wang S. Direct Observation of Incoherent Cherenkov Diffraction Radiation in the Visible Range. Phys Rev Lett 2018; 121:054802. [PMID: 30118307 DOI: 10.1103/physrevlett.121.054802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Indexed: 06/08/2023]
Abstract
We report on the observation of incoherent Cherenkov radiation emitted by a 5.3 GeV positron beam circulating in the Cornell electron-positron storage ring as the beam passes in the close vicinity of the surface of a fused silica radiator (i.e., at a distance larger than 0.8 mm). The shape of the radiator was designed in order to send the Cherenkov photons towards the detector, consisting of a compact optical system equipped with an intensified camera. The optical system allows both the measurements of 2D images and angular distribution including polarization study. The corresponding light intensity has been measured as a function of the distance between the beam and the surface of the radiator and has shown a good agreement with theoretical predictions. For highly relativistic particles, a large amount of incoherent radiation is produced in a wide spectral range. A light yield of 0.8×10^{-3} photon per particle per turn has been measured at a wavelength of 600±10 nm in a 2 cm long radiator and for an impact parameter of 1 mm. This will find applications in accelerators as noninvasive beam diagnostics for both leptons and hadrons.
Collapse
Affiliation(s)
- R Kieffer
- CERN, CH-1211 Geneva 23, Switzerland
| | - L Bartnik
- Cornell University, Ithaca, New York 14850, USA
| | | | - V V Bleko
- Tomsk Polytechnic University, Lenina avenue 30, Tomsk 634050, Russian Federation
| | - M Billing
- Cornell University, Ithaca, New York 14850, USA
| | - L Bobb
- Diamond Light Source, Oxfordshire OX11 0DE, United Kingdom
| | - J Conway
- Cornell University, Ithaca, New York 14850, USA
| | - M Forster
- Cornell University, Ithaca, New York 14850, USA
| | - P Karataev
- Royal Holloway, University of London, Egham, Surrey TW20 0EX, United Kingdom
| | - A S Konkov
- Tomsk Polytechnic University, Lenina avenue 30, Tomsk 634050, Russian Federation
| | - R O Jones
- CERN, CH-1211 Geneva 23, Switzerland
| | - T Lefevre
- CERN, CH-1211 Geneva 23, Switzerland
| | - J S Markova
- Tomsk Polytechnic University, Lenina avenue 30, Tomsk 634050, Russian Federation
| | - S Mazzoni
- CERN, CH-1211 Geneva 23, Switzerland
| | | | - A P Potylitsyn
- Tomsk Polytechnic University, Lenina avenue 30, Tomsk 634050, Russian Federation
| | - J Shanks
- Cornell University, Ithaca, New York 14850, USA
| | - S Wang
- Cornell University, Ithaca, New York 14850, USA
| |
Collapse
|
28
|
Lindsay CR, Jamal-Hanjani M, Forster M, Blackhall F. KRAS: Reasons for optimism in lung cancer. Eur J Cancer 2018; 99:20-27. [PMID: 29894909 DOI: 10.1016/j.ejca.2018.05.001] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 03/21/2018] [Accepted: 05/13/2018] [Indexed: 01/07/2023]
Abstract
Despite being the most frequent gain-of-function genetic alteration in human cancer, KRAS mutation has to date offered only limited potential as a prognostic and predictive biomarker. Results from the phase III SELECT-1 trial in non-small cell lung cancer (NSCLC) recently added to a number of historical and more contemporary disappointments in targeting KRAS mutant disease, including farnesyl transferase inhibition and synthetic lethality partners such as STK33. This narrative review uses the context of these previous failures to demonstrate how the knowledge gained from these experiences can be used as a platform for exciting advances in NSCLC on the horizon. It now seems clear that mutational subtype (most commonly G12C) of individual mutations is of greater relevance than the categorical evaluation of KRAS mutation presence or otherwise. A number of direct small molecules targeted to these subtypes are in development and have shown promising biological activity, with some in the late stages of preclinical validation.
Collapse
Affiliation(s)
- C R Lindsay
- Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, UK.
| | - M Jamal-Hanjani
- Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, UK; Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK
| | - M Forster
- Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, UK; Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK
| | - F Blackhall
- Division of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK; Cancer Research UK Lung Cancer Centre of Excellence, London and Manchester, UK
| |
Collapse
|
29
|
Sinharay R, Mithra S, Patel P, Ah-Moye A, Morrow S, Khiroya R, Falzon M, Borg E, Ahmed T, Forster M, Navani N. EGFR mutation specific immunohistochemistry revolutionises time to treatment with tyrosine kinase inhibitors (TKIs). Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30085-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
Forster M, Olmedo M, Calvo E, Moreno V, Lopez Criado M, Lopez-Vilariño J, Kahatt C, Lardelli P, Nuñez R, Soto-Matos A. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Lung Cancer 2018. [DOI: 10.1016/s0169-5002(18)30192-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Calvo E, Forster M, Moreno V, Olmedo M, Criado ML, Lopez-Vilariño J, Kahatt C, Soto-Matos A. MA 01.05 Activity and Safety of the Combination of PM01183 and Doxorubicin in Relapsed SCLC. Final Results of a Phase Ib Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann Oncol 2017; 28:2559-2566. [PMID: 28961837 PMCID: PMC5834091 DOI: 10.1093/annonc/mdx357] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion) on day 1 every 3 weeks (q3wk), and obtained preliminary evidence of antitumor activity for this combination in small-cell lung cancer (SCLC). PATIENTS AND METHODS Patients with advanced solid tumors received doxorubicin and PM01183 following a standard dose escalation design and expansion at the RD. Twenty-seven patients had relapsed SCLC: 12 with sensitive disease (platinum-free interval ≥90 days) and 15 with resistant disease (platinum-free interval <90 days). RESULTS Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose was the RD. In relapsed SCLC, treatment tolerance at the RD was manageable. Transient and reversible myelosuppression (including neutropenia, thrombocytopenia, and febrile neutropenia) was the main toxicity, managed with dose adjustment and colony-stimulating factors. Fatigue (79%), nausea/vomiting (58%), decreased appetite (53%), mucositis (53%), alopecia (42%), diarrhea/constipation (42%), and asymptomatic creatinine (68%) and transaminase increases (alanine aminotransferase 42%; aspartate aminotransferase 32%) were common, and mostly mild or moderate. Complete (n = 2, 8%) and partial response (n = 13, 50%) occurred in relapsed SCLC, mostly at the RD. Response rates at second line were 91.7% in sensitive disease [median progression-free survival (PFS)=5.8 months] and 33.3% in resistant disease (median PFS = 3.5 months). At third line, response rate was 20.0% (median PFS = 1.2 months), all in resistant disease. CONCLUSION Doxorubicin 50 mg/m2 and PM01183 4.0 mg flat dose on day 1 q3wk has shown remarkable activity, mainly in second line, with manageable tolerance in relapsed SCLC, leading to further evaluation of this combination within an ongoing phase III trial.
Collapse
Affiliation(s)
- E Calvo
- START Madrid - Oncology, HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid
| | - V Moreno
- START Madrid - Oncology, FJD (Hospital Fundación Jiménez Díaz), Madrid, Spain
| | - M Flynn
- Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK
| | - E Holgado
- START Madrid - Oncology, HM CIOCC, Hospital Madrid Norte Sanchinarro, Madrid
| | - M E Olmedo
- Department of Oncology, Hospital Ramon y Cajal, Madrid
| | | | - C Kahatt
- Clinical R&D, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain
| | | | - M Siguero
- Clinical R&D, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain
| | | | - M Cullell-Young
- Clinical R&D, Pharma Mar, S.A., Colmenar Viejo, Madrid, Spain
| | | | - M Forster
- Department of Oncology, University College of London Hospital and UCL Cancer Institute, London, UK;.
| |
Collapse
|
33
|
Vergote I, Dean E, Lassen U, de Bono J, Drew Y, Machiels JP, Nielsen D, Arkenau HT, Forster M, Jones R, Slomovitz B, Spicer J, Johnson M, Cornez N, Gennigens C, Fulton B, Lisby S, Basse L, Coleman R, Hong D. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Uccello M, Kushnir M, Mak G, Murias Henriquez C, Abbosh C, Papadatos-Pastos D, Newsom-Davis T, Ahmad T, Swanton C, Forster M, Lanman R, Faull I, Arkenau HT. Circulating tumour DNA (ctDNA) in the clinical management of patients (pts) with advanced non-small cell lung cancer (NSCLC): A single centre experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Olmedo Garcia M, Forster M, Calvo E, Moreno V, Lopez Criado M, Lopez-Vilarino de Ramos J, Kahatt C, Lardelli P, Luepke-Estefan X, Soto-Matos A. Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx386.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Forster M, Sessa C, Von Moos R, Brown N, Metaxas Y, Griguolo G, Lardelli P, Iglesias J, Fernandez-Teruel C, Jandali U, Soto-Matos S, Stathis A. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. Eur J Cancer 2017. [DOI: 10.1016/s0959-8049(17)30519-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Yip K, Conibear J, Woolf D, Tarver K, Willis B, Hall S, Sun F, Kuhan H, Lambourne B, Piskilidis P, Kussaibati R, Martin L, Satar NA, Gray C, Khan A, Doherty G, Prewett S, Smith M, Dancey G, Patterson D, Rimmer Y, Hollingdale A, Ingle C, Tasigiannopoulos Z, Aslam S, Waite K, Polychronis A, Ghafoor Q, Baijal S, Newsom-Davis T, Shah R, Forster M, Mulatero C, Greystoke A, Postmus P, Blackhall F, Gilligan D. 62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England. Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30112-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Darling GR, Forster M, Lin C, Liu N, Raval R, Hodgson A. Chiral segregation driven by a dynamical response of the adsorption footprint to the local adsorption environment: bitartrate on Cu(110). Phys Chem Chem Phys 2017; 19:7617-7623. [DOI: 10.1039/c7cp00622e] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Bitartrate, a strongly bound chiral modifier, is able to restructure its adsorption footprint on Cu(110) in response to local adsorbates.
Collapse
Affiliation(s)
- G. R. Darling
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| | - M. Forster
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| | - C. Lin
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| | - N. Liu
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| | - R. Raval
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| | - A. Hodgson
- Surface Science Research Centre and Department of Chemistry
- University of Liverpool
- Liverpool L69 3BX
- UK
| |
Collapse
|
39
|
Kordbacheh T, Chan C, Bossons A, Franks K, McDonald F, Forster M, Mendes R, Quezada S, Dovedi S, Ralph C, Popat S, Harrington K, Melcher A, Popple A, Illidge T, Faivre-Finn C. 164: PARIS: A phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30214-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Kordbacheh T, Chan C, Faivre-Finn C, Franks K, McDonald F, Forster M, Mendes R, Quezada S, Dovedi S, Ralph C, Popat S, Harrington K, Melcher A, Popple A, Illidge T. 168: PD-RAD: A translational study investigating PD-L1 expression after radiotherapy for non-small cell lung cancer (NSCLC). Lung Cancer 2017. [DOI: 10.1016/s0169-5002(17)30218-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
41
|
Mavrič T, Valant M, Forster M, Cowan A, Lavrenčič U, Emin S. Design of a highly photocatalytically active ZnO/CuWO 4 nanocomposite. J Colloid Interface Sci 2016; 483:93-101. [DOI: 10.1016/j.jcis.2016.08.019] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 08/08/2016] [Accepted: 08/10/2016] [Indexed: 02/07/2023]
|
42
|
Schaefer E, Braiteh F, Forster M, Talbot D, Chandler J, Richards D, Andre V, Estrem S, Pitou C, Tiu R, Brail L, Nikolinakos P. Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32990-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Brown N, Ganguli S, Kirkwood A, Imseeh G, Kristeleit R, Forster M, Meyer T. Clinical outcomes and predicting early death in early phase trials: The NIHR UCLH clinical research facility (CRF) experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Kristeleit R, Miller R, Sellers L, Brown N, Gougis P, Boyd A, Morris G, Payne H, Hughes S, Forster M, Linch M. A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumours. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Miller R, Brown N, Speirs A, Shaw H, Adeleke S, Gougis P, Bennett P, Meyer T, Swanton C, Forster M, Kristeleit R. The use of next generation sequencing (NGS) to guide patient selection for phase 1 clinical trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
46
|
Batchelor D, Aygül U, Dettinger U, Ivanovic M, Tournebize A, Mangold S, Forster M, Scherf U, Peisert H, Chassé T. Insight into the orientation of LBG polymer films by XANES experiment and calculation. Eur Polym J 2016. [DOI: 10.1016/j.eurpolymj.2016.04.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Knaapila M, Stepanyan R, Torkkeli M, Haase D, Fröhlich N, Helfer A, Forster M, Scherf U. Effect of side-chain asymmetry on the intermolecular structure and order-disorder transition in alkyl-substituted polyfluorenes. Phys Rev E 2016; 93:042504. [PMID: 27176345 DOI: 10.1103/physreve.93.042504] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Indexed: 11/07/2022]
Abstract
We study relations among the side-chain asymmetry, structure, and order-disorder transition (ODT) in hairy-rod-type poly(9,9-dihexylfluorene) (PF6) with two identical side chains and atactic poly(9-octyl-9-methyl-fluorene) (PF1-8) with two different side chains per repeat. PF6 and PF1-8 organize into alternating side-chain and backbone layers that transform into an isotropic phase at T^{ODT}(PF6) and T_{bi}^{ODT}(PF1-8). We interpret polymers in terms of monodisperse and bidisperse brushes and predict scenarios T^{ODT}<T_{bi}^{ODT} and T^{ODT}∼T_{bi}^{ODT} for high and low grafting densities (the side-chain length above or below the average grafting distance). Calorimetry and x-ray scattering indicate the condition T^{ODT}(PF6)∼T_{bi}^{ODT}(PF1-8) following the low grafting prediction. PF6 side chains coming from the alternating backbone layers appear as two separate layers with thickness H(PF6), whereas PF1-8 side chains appear as an indistinguishable bilayer with a half thickness H_{bilayer}(PF1-8)/2≈H(PF6). The low grafting density region is structurally possible but not certain for PF6 and confirmed for PF1-8.
Collapse
Affiliation(s)
- M Knaapila
- Department of Physics, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark
| | - R Stepanyan
- Materials Science Centre, DSM Research, 6160 MD Geleen, The Netherlands
| | - M Torkkeli
- Department of Physics, University of Helsinki, 00014 Helsinki, Finland
| | - D Haase
- MAX IV Laboratory, Lund University, 22100 Lund, Sweden
| | - N Fröhlich
- Macromolecular Chemistry Group (buwmakro), Bergische Universität Wuppertal, 42119 Wuppertal, Germany
| | - A Helfer
- Macromolecular Chemistry Group (buwmakro), Bergische Universität Wuppertal, 42119 Wuppertal, Germany
| | - M Forster
- Macromolecular Chemistry Group (buwmakro), Bergische Universität Wuppertal, 42119 Wuppertal, Germany
| | - U Scherf
- Macromolecular Chemistry Group (buwmakro), Bergische Universität Wuppertal, 42119 Wuppertal, Germany
| |
Collapse
|
48
|
Ruparel M, Ejaz A, Chauhan N, Ridge M, Chung D, Succony L, Banka R, Thakrar R, Kumar N, Sage E, Forster M, Janes S, Newsom-Davis T, Ahmad T, Navani N. 23 Characteristics of lung cancer patients diagnosed following emergency admission. Lung Cancer 2016. [DOI: 10.1016/s0169-5002(16)30040-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
49
|
Abstract
Surface chirality arising from self-organized molecular monolayers may manifest both a handedness and footedness, leading to a dual level of chiral expression.
Collapse
Affiliation(s)
- M. Forster
- Surface Science Research Centre
- Department of Chemistry
- University of Liverpool
- Liverpool
- UK
| | - R. Raval
- Surface Science Research Centre
- Department of Chemistry
- University of Liverpool
- Liverpool
- UK
| |
Collapse
|
50
|
Eychmüller S, Forster M, Gudat H, Lütolf UM, Borasio GD. Undergraduate palliative care teaching in Swiss medical faculties: a nationwide survey and improved learning objectives. BMC Med Educ 2015; 15:213. [PMID: 26614121 PMCID: PMC4662810 DOI: 10.1186/s12909-015-0485-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2014] [Accepted: 11/09/2015] [Indexed: 05/26/2023]
Abstract
BACKGROUND In 2007, a first survey on undergraduate palliative care teaching in Switzerland has revealed major heterogeneity of palliative care content, allocation of hours and distribution throughout the 6 year curriculum in Swiss medical faculties. This second survey in 2012/13 has been initiated as part of the current Swiss national strategy in palliative care (2010 - 2015) to serve as a longitudinal monitoring instrument and as a basis for redefinition of palliative care learning objectives and curriculum planning in our country. METHODS As in 2007, a questionnaire was sent to the deans of all five medical faculties in Switzerland in 2012. It consisted of eight sections: basic background information, current content and hours in dedicated palliative care blocks, current palliative care content in other courses, topics related to palliative care presented in other courses, recent attempts at improving palliative care content, palliative care content in examinations, challenges, and overall summary. Content analysis was performed and the results matched with recommendations from the EAPC for undergraduate training in palliative medicine as well as with recommendations from overseas countries. RESULTS There is a considerable increase in palliative care content, academic teaching staff and hours in all medical faculties compared to 2007. No Swiss medical faculty reaches the range of 40 h dedicated specifically to palliative care as recommended by the EAPC. Topics, teaching methods, distribution throughout different years and compulsory attendance still differ widely. Based on these results, the official Swiss Catalogue of Learning Objectives (SCLO) was complemented with 12 new learning objectives for palliative and end of life care (2013), and a national basic script for palliative care was published (2015). CONCLUSION Performing periodic surveys of palliative care teaching at national medical faculties has proven to be a useful tool to adapt the national teaching framework and to improve the recognition of palliative medicine as an integral part of medical training.
Collapse
Affiliation(s)
- S Eychmüller
- Center for Palliative Care, University hospital, Inselspital Berne, Freiburgstrasse 28, CH- 3010, Berne, Switzerland.
| | - M Forster
- Center for Palliative Care, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
| | - H Gudat
- Hospice "Im Park", Arlesheim, Switzerland.
| | - U M Lütolf
- Department of Radio-Oncology, University Hospital Zurich (until Dec 2012), Zurich, Switzerland.
| | - G D Borasio
- Service de Soins Palliatifs, University Hospital Lausanne, Lausanne, Switzerland.
| |
Collapse
|